|
Now you can ask whether any of
the standard anti-tuberculosis treatments exhibit the pharmacokinetic mismatch problem.
This figure shows data for rifater, a common three-drug anti-tuberculosis agent. What you
see is that isoniazid will tend to be above its MIC alone for more than a third of the
dosing time. A combination of patient noncompliance, HIV disease, and pharmacokinetic
mismatch may contribute to the increasing frequency of INH-resistance. Go to Part II of this
lecture
|
Go to Comment Form |
|